Repligen Co. (NASDAQ:RGEN) Position Increased by Geneva Capital Management LLC

by · The Cerbat Gem

Geneva Capital Management LLC grew its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 8.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 138,677 shares of the biotechnology company’s stock after acquiring an additional 10,908 shares during the quarter. Geneva Capital Management LLC’s holdings in Repligen were worth $20,638,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Vanguard Group Inc. increased its stake in shares of Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after purchasing an additional 21,719 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after purchasing an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC raised its position in shares of Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after purchasing an additional 199,322 shares during the period. Thrivent Financial for Lutherans grew its stake in Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after buying an additional 425,061 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Repligen by 14.4% in the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock worth $84,387,000 after purchasing an additional 71,274 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of RGEN opened at $148.59 on Wednesday. The stock’s fifty day simple moving average is $141.34 and its 200-day simple moving average is $144.87. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on RGEN shares. UBS Group decreased their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. Stephens reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Check Out Our Latest Analysis on RGEN

Repligen Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

See Also

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN – Free Report).